Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Leases (2019 - 2023)

Beam Therapeutics (BEAM) has disclosed Capital Leases for 5 consecutive years, with $304000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Capital Leases fell 78.1% to $304000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $304000.0, a 78.1% decrease, with the full-year FY2022 number at $1.2 million, down 61.62% from a year prior.
  • Capital Leases was $304000.0 for Q3 2023 at Beam Therapeutics, down from $875000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $5.3 million in Q1 2020 to a low of $304000.0 in Q3 2023.
  • A 5-year average of $3.0 million and a median of $3.3 million in 2021 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: increased 20.02% in 2020, then plummeted 78.1% in 2023.
  • Beam Therapeutics' Capital Leases stood at $4.4 million in 2019, then increased by 20.02% to $5.3 million in 2020, then crashed by 43.2% to $3.0 million in 2021, then crashed by 61.62% to $1.2 million in 2022, then tumbled by 73.66% to $304000.0 in 2023.
  • Per Business Quant, the three most recent readings for BEAM's Capital Leases are $304000.0 (Q3 2023), $875000.0 (Q2 2023), and $983000.0 (Q1 2023).